作者: Gorup, Luiz Fernando ; de Castilho Alves Morais, Elizângela Maria ; Figueiredo, Eduardo Costa ; Arnoni, Estela Domingos ; Rosa, Mariana Azevedo ; Moreira, Ailton José ; Mendes, Tássia Venga

Magnetic particle spray mass spectrometry (MPS-MS), an innovative ambient ionization technique proposed by our research group, was employed to determine beta-blockers in human plasma samples. A dispersive solid phase extraction of atenolol, metoprolol, labetalol, propranolol, nadolol, and pindolol was carried out using magnetic molecularly imprinted polymer (M-MIP) particles that were attached to the tip of a metal probe, which was placed in the mass spectrometer inlet. A solvent (1% formic acid in methanol) was dispensed on the particles, and the Taylor cone was formed around them (in high voltage). The analytes were desorbed/ionized and determined by a triple quadrupole mass spectrometer. M-MIP was synthesized with oxprenolol as a pseudo-template, demonstrating good selectivity to beta-blockers compared with no-analog molecules, with an adsorption process occurring in monolayers, according to isotherm studies. Kinetic experiments indicated chemisorption as the predominant M-MIP/analyte interaction. The analytical curves were linear (R² > 0.98), and the limit of quantification was 3 µg L^-1 for all the analytes. Limits of detection ranged from 0.64 to 2.41 µg L^-1. Precisions (relative standard deviation) and accuracies (relative error) ranged from 3.95 to 21.20% and -17.05 to 18.93%, respectively. MPS-MS proved to be a simple, sensitive, and advantageous technique compared with conventional approaches. The analyses were fast, requiring no chromatographic separation and without ionic suppression. The method is aligned with green chemistry principles, requiring minimal sample, solvent, and sorbent amounts. MPS-MS successfully integrates sample preparation and ambient ionization mass spectrometry and holds great potential for application with other sorbents, samples, and analytes.

2023-04-03·Neurological Research

Beta-blocker carteolol and oxprenolol produce cutaneous analgesia in response to needle pinpricks in the rat

Article

作者: Chou, An-Kuo ; Chen, Yu-Wen

BACKGROUNDThis present study was undertaken to determine whether beta-blockers produce the cutaneous analgesic effect, comparing them with the long-acting local anesthetic bupivacaine.METHODSUsing a rat model of infiltrative cutaneous analgesia, the effect of 5 beta-blockers (oxprenolol, carteolol, butaxamine, metoprolol, and acebutolol) and bupivacaine was compared and eventually combined with epinephrine.RESULTSAmong 5 beta-blockers, oxprenolol exhibited the most potent and the longest duration of cutaneous analgesia. In dose-response studies, the rank order of efficacy (ED₅₀ [50% effective dose]) was bupivacaine (0.40 [0.35-0.47] μmol) > oxprenolol (2.33 [2.06-2.64] μmol) > carteolol (4.86 [4.27-5.53] μmol) (p< 0.01). Carteolol provoked a longer duration of analgesia (p< 0.01) than oxprenolol or bupivacaine on an equipotent basis (ED₂₅, ED₅₀, and ED₇₅). Adding epinephrine 1:200,000 to drug preparations (carteolol, oxprenolol, and bupivacaine) at ED₉₅ had a peripheral action in prolonging the duration of action.CONCLUSIONSOxprenolol and carteolol had greater potencies and longer durations of cutaneous analgesia than butaxamine, metoprolol, and acebutolol. Oxprenolol produced a similar duration of action when compared to bupivacaine, while carteolol had a greater duration of action than bupivacaine. Cutaneous analgesia of oxprenolol (or carteolol) plus adrenaline was greater than that of bupivacaine plus adrenaline.

2023-02-01·Journal of Cachexia, Sarcopenia and Muscle

The atypical β‐blocker S‐oxprenolol reduces cachexia and improves survival in a rat cancer cachexia model

Article

作者: Anker, Markus S. ; Millman, Oliver ; Álvarez Ladrón, Natalia ; Jové, Queralt ; von Haehling, Stephan ; Szymczyk, Agata ; Oosterlee, Annemijn ; Yuan, Luping ; Coats, Andrew J.S. ; Springer, Jochen ; Argiles, Josep M. ; Alves de Lima Junior, Edson ; López‐Soriano, Francisco Javier ; Anker, Stefan D. ; Palus, Sandra ; Busquets, Silvia

AbstractBackgroundBeta‐blockers and selected stereoisomers of beta‐blockers, like bisoprolol and S‐pindolol (ACM‐001), have been shown to be effective in preclinical cancer cachexia models. Here, we tested the efficacy of stereoisomers of oxprenolol in two preclinical models of cancer cachexia—the Yoshida AH‐130 rat model and the Lewis lung carcinoma (LLC) mouse model.Methods and ResultsIn the Yoshida AH130 hepatoma rat cancer cachexia model and compared with placebo, 50 mg/kg/d S‐oxprenolol (HR: 0.49, 95% CI: 0.28–0.85, P = 0.012) was superior to 50 mg/kg/d R‐oxprenolol (HR: 0.83, 95% CI 0.38–1.45, P = 0.51) in reducing mortality (= reaching ethical endpoints). Combination of the three doses (12.5, 25 and 50 mg/kg/d) that had a significant effect on body weight loss in the S‐oxprenolol groups vs the same combination of the R‐oxprenolol groups lead to a significantly improved survival of S‐oxprenolol vs R‐oxprenolol (HR: 1.61, 95% CI: 1.08–2.39, P = 0.0185). Interestingly, there is a clear dose dependency in S‐oxprenolol‐treated (5, 12.5, 25 and 50 mg/kg/d) groups, which was not observed in groups treated with R‐oxprenolol. A dose‐dependent attenuation of weight and lean mass loss by S‐oxprenolol was seen in the Yoshida rat model, whereas R‐oxprenolol had only had a significant effect on fat mass. S‐oxprenolol also non‐significantly reduced weight loss in the LLC model and also improved muscle function (grip strength 428 ± 25 and 539 ± 37 g/100 g body weight for placebo and S‐oxprenolol, respectively). However, there was only a minor effect on quality of life indicators food intake and spontaneous activity in the Yoshida model (25 mg/kg/S‐oxprenolol: 11.9 ± 2.5 g vs placebo: 4.9 ± 0.8 g, P = 0.013 and also vs 25 mg/kg/d R‐oxprenolol: 7.5 ± 2.6 g, P = 0.025). Both enantiomers had no effects on cardiac dimensions and function at the doses used in this study. Western blotting of proteins involved in the anabolic/catabolic homoeostasis suggest that anabolic signalling is persevered (IGF‐1 receptor, Akt) and catabolic signalling is inhibited (FXBO‐10, TRAF‐6) by S‐pindolol, but not he R‐enantiomer. Expression of glucose transporters Glut1 and Glut 4 was similar in all groups, as was AMPK.ConclusionsS‐oxprenolol is superior to R‐oxprenolol in cancer cachexia animal models and shows promise for a human application in cancer cachexia.

项与氧烯洛尔相关的新闻（医药）

2024-11-14

·GlobeNewswire-Health Care

Actimed Therapeutics Announces Professor David Ebsworth to Become Executive Chairman

Professor David Ebsworth to work closely alongside CEO Robin BhattacherjeeWill focus on fund raising efforts to support the planned IMPACT Phase 2b/3 trial for S-pindolol benzoate in cancer cachexiaProfessor Stefan Anker, Co-Founder of Actimed and Chair of the Scientific Advisory Board, also joins the Board of Directors London, UK – 14th November 2024. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting disorders, announces that Professor David Ebsworth will assume the role of Executive Chairman of Actimed. At the same time, Professor Stefan Anker, Founder and Chair of the Actimed Scientific Advisory Board, will join the Board of the Company as a Non-Executive Director. David has been Non-Executive Chairman of Actimed Therapeutics since April 2018. He has over 40 years of experience in the healthcare industry and is a past CEO of Galenica AG, Vifor Pharma AG and past global head of the Pharmaceutical Division of Bayer AG. David has chaired numerous private and public pharmaceutical companies and served on many Boards as either Chairman of the audit, remuneration or nominations and governance committees. David is Chair of the Supervisory Board at Synlab AG and Board member at Sartorius AG. David also currently serves as Chairman of Nasdaq listed Verona Pharma PLC, which he moved from AIM to Nasdaq in 2020. Verona recently gained approval for and has successfully launched Ohtuvayre (ensifentrine). David will work closely in partnership with CEO Robin Bhattacherjee to support the Company’s fund-raising activities to finance the planned Phase 2b/3 IMPACT clinical trial programme for Actimed’s lead asset, S-pindolol benzoate, in cancer cachexia. Actimed received FDA approval of its Investigational New Drug (IND) application for the IMPACT programme in August 2023. The Company plans to dose patients in 2025. Professor Stefan Anker, MD, PhD, co-founded Actimed Therapeutics in 2017, having previously founded Myotec (later renamed PsiOxus Therapeutics). Stefan has 30 years of academic research experience in cachexia and clinical trials development. He is founding Editor-in-Chief of the Journal of Cachexia, Sarcopenia and Muscle as well as the founding president of the International Society on Sarcopenia, Cachexia and Wasting Disorders. Stefan has been and is a member of more than 50 international clinical trial steering committees and is a named author on over 1,300 research papers. As Actimed advances the clinical development of S-pindolol benzoate, Stefan’s expertise and knowledge will provide important support to the Board and the Company. Robin Bhattacherjee, Chief Executive Officer of Actimed Therapeutics commented “I greatly look forward to David taking on the role of Executive Chairman and dedicating more time to advancing our efforts to bring S-pindolol benzoate to patients. David’s industry track record, contact network and Board expertise speak for themselves and will further strengthen our ability to finance and complete our planned clinical programme for this highly promising asset.” David Ebsworth, Executive Chair of Actimed added “I look forward to working more closely with Robin to achieve our objectives. I am deeply committed to ensuring success for Actimed in our mission to transform care for the many patients suffering from cancer cachexia and other muscle wasting disorders. Cancer cachexia remains a poorly treated condition with few recent advances in therapy. At Actimed, I believe we have an exciting opportunity to advance the standard of care when we successfully finance and complete the clinical development of S-pindolol benzoate and I am pleased to provide my full support to Robin and the Leadership Team in pursuit of this.” *** About Actimed Therapeutics Actimed Therapeutics is a clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cachexia and other muscle wasting disorders, to transform the care of an underserved and vulnerable patient population. Cachexia is a wasting disease that is associated with cancer and other serious chronic illnesses and with significant morbidity and mortality. A significant number of cancer patients suffer from cachexia, and it is estimated that cachexia is responsible for up to 20% of all cancer deaths. Despite its prevalence and devastating clinical effects, there is no globally approved drug for the treatment or prevention of cancer-related cachexia. Actimed’s lead product, S-pindolol benzoate (ACM-001.1), targets multiple pathways that drive cachexia and has generated promising proof of concept Phase 2a clinical data in cachexia patients. Actimed is currently preparing for further clinical studies in cancer cachexia having received an Investigational New Drug (IND) approval from FDA for this programme in August 2023. Actimed also owns the global rights to its second asset, S-oxprenolol, which is being developed by the Company for the muscle wasting seen in amyotrophic lateral sclerosis (ALS) where loss of body mass and muscle wasting may impact survival. Actimed has licensed the global rights to develop and commercialise S-oxprenolol for cancer cachexia and any other indications outside of ALS to US company Faraday Pharmaceuticals. FOR MORE INFORMATIONActimed Therapeuticswww.actimedtherapeutics.com MEDiSTRAVA Frazer Hall, Erica HollingsworthTel: +44 (0)203 928 6900Email: actimed@medistrava.com ___________________________

临床2期高管变更上市批准

2024-09-13

·药渡Daily

【药渡药闻报告-创新药篇】-2024年第35期/总第156期

全球药物批准/研发动态 01 全球新药批准情况根据药渡数据统计分析，本次统计周期（2024.08.31-09.06）全球（不含中国）共有1个新药获批上市。其中，新适应症批准1个。与上个统计周期相比，本次减少9个批准新药。 9月5日，Travere Therapeutics宣布，FDA已完全批准FILSPARI（Sparsentan）用于减缓有疾病进展风险的原发性IgAN成人患者的肾功能下降。FILSPARI是唯一一种口服、每日一次的非免疫抑制药物，通过阻断IgAN疾病进展的两条关键途径（内皮素-1和血管紧张素II）直接靶向肾脏肾小球损伤。在对404名随机分配患者的最终分析中，与厄贝沙坦相比，FILSPARI显著降低了从基线到第110周的肾功能下降率。与活性对照厄贝沙坦相比，在第36周观察到的对蛋白尿的积极治疗效果在两年测量期内持续存在。PROTECT研究的其他结果表明，FILSPARI耐受性良好，具有明确定义的安全性。全球（不含中国）新药批准情况（部分） 02 全球新药申报进展根据药渡数据统计分析，本次统计周期（2024.08.31-09.06）全球（不含中国）共有3个新药申报上市。其中，NDA申报1个，BLA申报1个，细胞疗法1个。本次NDA/BLA申报数量与上次统计周期相同。 9月4日，AXSM宣布FDA已确认重新提交AXS-07的新药申请，用于治疗急性偏头痛。AXS-07由MoSEIC™美洛昔康和利扎曲坦组成。美洛昔康快速吸收，同时保持较长的血浆半衰期。美洛昔康是一种COX-2优先非甾体抗炎药，利扎曲坦是一种5-HT1B/1D激动剂。AXS-07旨在快速缓解偏头痛，减少症状复发。 NDA/BLA申报根据药渡数据统计分析，本次统计周期（2024.08.31-09.06）全球（不含中国）共有2个药物获监管机构特殊资格认定。其中，化学药1个，生物药1个。与上次统计周期相比，本次减少4个获监管机构特殊资格认定的药物。 9月4日，Actimed宣布FDA已授予S-oxprenolol（ACM-002）孤儿药资格认定，用于治疗肌萎缩侧索硬化症（ALS）。ALS是一种毁灭性的孤儿病，具有高度、未满足的医疗需求，S-oxprenolol在该适应症中生成的早期非临床数据表明，它可能在满足这一服务不足的患者群体的一些重要需求方面发挥潜在作用。同日，信达生物宣布其PD-1/IL-2α-bias双特异性抗体融合蛋白IBI363获得FDA授予快速通道资格，拟定适应症为既往接受过至少一线含PD-1/L1检查点抑制剂系统性治疗后进展的局部晚期或转移性黑色素瘤（脉络膜黑色素瘤除外）。IBI363是PD-1/IL-2双特异性融合蛋白，同时具有阻断PD-1/PD-L1通路和激活IL-2通路两项功能。在37例既往接受过免疫治疗的黑色素瘤患者接受了1mg/kg IBI363治疗并至少接受了一次基线后肿瘤评估的患者中，11例获得了客观缓解，包括1例CR和10例PR，ORR和DCR分别为29.7%和73.0%。特殊资格认定情况（部分） 03 全球新药研发进展根据药渡数据统计分析，本次统计周期（2024.08.31-09.06）全球（不含中国）新药临床研发状态更新共计27条，涉及肿瘤、血液和淋巴疾病、遗传代谢病、神经疾病以及免疫系统疾病等共计9个领域。其中，遗传和代谢领域及感染领域临床进展更新居各领域之首，均为5条：遗传和代谢病涉及化学药3条，生物药2条；感染涉及化学药2条，生物药1条，疫苗2条。 9月2日，锐正基因自主研发的针对转甲状腺素蛋白淀粉样变性（ATTR）的产品ART001近日美国IND申请通过。临床研究数据表明，受试者在用药4周后直至24周，高剂量组的外周TTR蛋白水平较基线平均下降超过90%。目前，所有受试者均已跟进36周或以上，药效依然保持稳定。ART001目前是中国唯一达到90%TTR敲降的体内基因编辑产品。 9月6日，GSK宣布了Nucala（Mepolizumab）的III期临床试验（MATINEE）积极结果。Nucala（美泊利单抗）是一种靶向成人慢性阻塞性肺病白细胞介素5（IL-5）的单克隆抗体。MATINEE在吸入维持治疗中加入Nucala达到了其主要终点，研究结果显示，与安慰剂相比，接受长达104周的患者中度/重度恶化的年化率降低具有统计学意义和临床意义，初步安全性结果与Nucala的已知安全性特征一致。全球新药研发进展详情（部分） 04 全球医药交易事件本次统计周期（2024.08.31-09.06）全球（含中国）医药交易时间共计26起，涉及药物权益转让、公司并购等多起交易事件。全球医药交易时间汇总表（部分）国内药物批准/研发动态 01 国内新药批准情况根据药渡数据统计分析，本次统计周期（2024.08.31-09.06）国内共有4个新药获NMPA批准上市。其中，NDA批准1个，BLA批准2个，新适应症批准1个。与上次统计周期相比，本次增加1个NMPA批准新药。 9月3日，菲洋生物宣布，地舒单抗注射液（恒盖®）获得国家药品监督管理局批准上市，用于治疗骨折高风险的男性和绝经后妇女的骨质疏松症。恒盖®与原研药普罗力®进行了严格的药学、非临床和临床的全面对比，结果表明，两者药学和非临床方面具有高度相似性；III期临床试验显示，主要疗效指标——受试者第12个月腰椎BMD较基线变化率在等效范围内，其他次要疗效指标和安全性指标也无统计学差异。 9月3日，NMPA批准了南京圣和药业的甲磺酸瑞厄替尼片，用于具有表皮生长因子受体（EGFR）外显子19缺失或外显子21（L858R）置换突变的局部晚期或转移性非小细胞肺癌（NSCLC）成人患者的一线治疗。III期临床研究结果显示，与吉非替尼组相比，本品显示出具有统计学和临床意义的PFS获益，瑞厄替尼组和吉非替尼组的中位PFS分别为19.3个月和9.8个月（HR=0.46，95% CI：0.33，0.65，p<0.0001）。国内新药批准情况（部分） 02 国内新药临床默示许可进展根据药渡数据统计分析，本次统计周期（2024.08.31-09.06）国内共有17个新药获临床默示许可，涉及24个受理号。其中，化学药8个，治疗用生物制品8个，预防用生物制品1个。与上次统计周期相比，本次减少22个临床默示许可获批受理号。本周国内新药临床默示许可进展（部分） 03 国内新药申报进展根据药渡数据统计分析，本次统计周期（2024.08.31-09.06）国内共有9个新药申报上市，涉及11个受理号。其中，化药4个，治疗用生物制品4个，预防用生物制品1个。与上个统计周期相比，本次减少6个新药申报上市受理号。国内新药申报上市情况根据药渡数据统计分析，本次统计周期（2024.08.31-09.06）国内共有36个新药申报临床，涉及53个受理号。其中，化学药17个，治疗用生物制品15个，预防用生物制品4个。与上次统计周期相比，本次减少7个临床申报受理号。国内新药临床申报情况（部分）根据药渡数据统计分析，本次统计周期（2024.08.31-09.06）国内共有5个药物获NMPA特殊资格认定。其中，化学药4个，生物药1个。与上次统计周期相比，本次增加4个获监管机构特殊资格认定的药物。 9月2日，NMPA药品审评中心官网最新公示，恒瑞医药注射用瑞康曲妥珠单抗拟纳入优先审评，用于既往接受过至少一种系统治疗的局部晚期或转移性HER2突变成人非小细胞肺癌患者的治疗。瑞康曲妥珠单抗由抗HER2抗体曲妥珠单抗、可裂解连接子及拓扑异构酶I抑制剂有效载荷SHR169265组合而成。临床研究结果显示全剂量组ORR为38.1%，DCR为90.5%，中位DOR为10.3个月，中位PFS为9.5个月；4.8mg/kg剂量组（RP2D, N=43）ORR为41.9%，DCR为95.3%，DOR为13.7个月，中位PFS为8.4个月。 9月6日，CDE官网公示，苏州赞荣医药申报的ZN-A-1041肠溶胶囊拟纳入突破性治疗品种，适应症为：ZN-A-1041联合卡培他滨和曲妥珠单抗用于既往接受过含曲妥珠单抗治疗进展的HER2阳性晚期脑转移乳腺癌患者。ZN-A-1041是一款口服小分子HER2靶向小分子抑制剂，具备高度血脑屏障通透性。研究结果显示，在19例至少两次肿瘤评估的脑转移乳腺癌患者中，ZN-1041联合卡培他滨和曲妥珠单抗的总ORR为78.9%，iORR为73.7%，DCR为100%。。国内监管机构特殊资格认定药物 04 国内新药研发进展根据药渡数据统计分析，本次统计周期（2024.08.31-09.06）国内新药临床研发状态更新共计2条，涉及肿瘤和心血管疾病共计2个领域。其中，化学药1条，生物药1条。与上次统计周期相比，本次减少1条国内新药临床研发状态更新。近日，恒瑞医药降脂创新药SHR-1918一项I期研究亮相2024 ESC年会。与安慰剂相比，SHR-1918在降低血清LDL-C和TG水平方面表现出显著效果，并具有剂量依赖性，300mg及以上剂量水平的LDL-C降低超过30%，持续64天以上，最高达49.1%；TG降低超过50%，持续85天以上，最高达82.8%。SHR-1918单次皮下注射在健康受试者中显示出良好的耐受性和药代动力学特性，且在给药后显示出良好的剂量-暴露-效应关系。SHR-1918作为一种潜在的降脂药物，能够有效降低LDL-C和TG水平。 9月5日，威尚生物医药宣布其新型EGFR抑制剂WSD0922完成首例受试者入组。WSD0922具有穿透血脑屏障潜力的第四代EGFR/EGFRvIII靶向抑制剂。7月8日，WSD0922获NMPA批准在中国开展I期桥接及II期扩展临床试验，用于经一线三代EGFR抑制剂治疗进展具C797S突变的晚期/转移性非小细胞肺癌。国内新药研发进展 05 国内新药研发领域政策法规动态本周暂无相关政策法规动态。 06 国内新药研发领域热点新闻赛诺菲BTK抑制剂III期成功，有效延缓多发性硬化症残疾进展 9月2日，赛诺菲发布公告称其BTK抑制剂Tolebrutinib在HERCULES III期研究中达到主要终点——与安慰剂相比，该药物可以有效延缓残疾进展。值得注意的是，这是首个也是唯一一个显示非复发继发性进行性多发性硬化症（MS）残疾积累减少的研究。关于MS MS是一种慢性、免疫介导的神经退行性疾病，随着时间的推移，会导致不可逆转的残疾。身体和认知障碍导致健康状况逐渐恶化，生活质量下降，影响患者的护理和预期寿命。目前，MS仍然不能治愈，残疾积累是MS中未得到满足的重要医疗需求。迄今为止，当前疗法……更多资讯，请阅读原文 9月3日，益诺思正式登陆科创板，恒瑞医药是其最大客户 9月3日，益诺思正式在科创板上市，发行总股份1.41亿股，每股19.06元。当下的国内CXO行业，沉浸在一片悲观的情绪中。内部环境中，行业正在经历结构性调整镇痛，无人能够幸免，各大参与者大打价格战，增量市场正逐步萎缩为存量市场；外部环境中，地缘政治举起“制裁”的大棒迎来来袭，这一棒威力值巨大，伤筋动骨在所难免。在这样的氛围中，益诺思的上市能否给这个动荡中的行业提振一点士气？更多资讯，请阅读原文 2024H1盘点：A股CXO市值蒸发2100亿元，仅一家幸免截至8月31日，A股5349家上市公司中已有5346家半年报披露完毕。其中，495家医药股中有250家实现了净利润同比增长，占比50.5%。从内外部环境来看，医药行业整体上已有触底反弹的迹象，但作为“卖水人”的CXO行业却仍在持续下探。A股市场所属同花顺行业包含医疗研发外包的29家上市公司中，28家股价下跌（以8月30日收盘价计，下同），仅诺泰生物一家得以幸免，占比96.6%，平均跌幅39.31%。 CXO的底在哪里，未来还值得期待吗？更多资讯，请阅读原文咨询、合作请联系作者小D有话说为方便读者阅读及保存，我们将周报原文整理成了PDF版本，如需获取全文，可点击最上方蓝字，在药渡Daily公众号后台回复“0913创新药周报”，即可下载。

孤儿药上市批准快速通道

2024-09-04

·GlobeNewswire-Health Care

Actimed Therapeutics Announces US FDA Grant of Orphan Drug Designation to S-oxprenolol (ACM-002) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

London, UK – 4th September 2024. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting disorders, announces that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to S-oxprenolol (ACM-002) for the treatment of amyotrophic lateral sclerosis (ALS). ALS (also known as Lou Gehrig’s disease) is a progressive, fatal neuromuscular disease that affects nerve cells in the brain and spinal cord, eventually leading to a loss of muscle control and paralysis. ALS prevents motor neurons sending impulses from the brain and spinal cord to the muscles, causing muscle atrophy and weakness and has a mean survival of 3.5 years. Voluntary muscle action is progressively lost and in late-stage ALS patients may have difficulty communicating, swallowing, moving, and breathing. There is currently no cure for ALS. Cachexia, a complex wasting disease, may occur in the early stages of ALS and has a significant impact on quality of life, proving terminal in some patients. In pre-clinical ALS models, S-oxprenolol has demonstrated significant benefits including slowing disease progression, improvement in survival, attenuation of muscle loss, motor neuron protection, reduction in loss of body mass and improvements in lean body mass1. Robin Bhattacherjee, Chief Executive Officer of Actimed Therapeutics commented “We are pleased to receive Orphan Drug Designation for S-oxprenolol in ALS, where loss of body mass and muscle wasting can have a significant impact on survival. ALS is a devastating orphan disease of high, unmet medical need and the early non-clinical data we have generated for S-oxprenolol in this indication suggest that it could have a potential role in meeting some of the important needs of this under-served patient population”. FDA Orphan Drug Designation is granted to investigational therapies which are intended for the safe and effective treatment, diagnosis or prevention of rare diseases or conditions that affect fewer than 200,000 people in the United States. Orphan Drug Designation provides several benefits to drug developers, including certain development cost benefits in the US, increased FDA interaction and eligibility for seven-year market exclusivity following approval. *** About Actimed Therapeutics Actimed Therapeutics is a clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of muscle wasting disorders to transform the care of an underserved and vulnerable patient population. The lead area of focus for Actimed is specifically in cachexia. Cachexia is a wasting disease that is associated with cancer and other serious chronic illnesses and with significant morbidity and mortality. A significant number of cancer patients suffer from cachexia2 and it is estimated that cachexia is responsible for up to 20% of all cancer deaths3. A recent meta-analysis demonstrated that cachexia was associated with an 82% higher relative risk of mortality in patients with NSCLC versus no cachexia4. Despite its prevalence and devastating clinical effects, there is no globally approved drug for the treatment or prevention of cancer-related cachexia. The lead product of Actimed, S-pindolol benzoate (ACM-001.1) targets multiple pathways that drive cachexia and has generated promising proof of concept Phase 2a clinical data in cachexia patients. Actimed is currently preparing for further clinical studies in cancer cachexia having received an Investigational New Drug (IND) approval from FDA for this programme in August 2023. Actimed also owns the global rights to its second asset, S-oxprenolol, which is being developed by the Company for the muscle wasting seen in amyotrophic lateral sclerosis (ALS) where loss of body mass and muscle wasting may impact survival5. Actimed has licensed the global rights to develop and commercialise S-oxprenolol for cancer cachexia and any other indications outside of ALS to US company Faraday Pharmaceuticals. FOR MORE INFORMATIONActimed Therapeuticswww.actimedtherapeutics.com MEDiSTRAVA ConsultingFrazer Hall, Erica HollingsworthTel: +44 (0)203 928 6900Email: actimed@medistrava.com ___________________________ 1Suzuki et al, JCSM 2018; 9, 183-212. (Poster 5-17, page 200)2 Anker M et al., J. Cachexia, Sarcopenia and Muscle; 2019: 10: 22 – 243 Argilés JM et al, Nat Rev Cancer 2014; 14:754-624 Bonomi P. et al. The mortality burden of cachexia in patients with non-small-cell lung cancer: A meta-analysis; International Conference of Sarcopenia, Cachexia and Wasting Disorders, June 17 – 18 2023, Stockholm, abstract 2-18, page 1395Wolf J et al., PMID 28184974 DOI: 10.1007/s00115-117-0293

临床2期孤儿药

100 项与氧烯洛尔相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08318	氧烯洛尔	C07AA02	DB01580

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
心绞痛	中国	北京万辉双鹤药业有限责任公司	-
心律失常	中国	北京万辉双鹤药业有限责任公司	-
高血压	中国	北京万辉双鹤药业有限责任公司	-